Quantum Biopharma (QNTM) to Post Earnings on Thursday

Quantum Biopharma (NASDAQ:QNTM) is anticipated to post its results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.4116) per share for the quarter.

Quantum Biopharma Stock Performance

NASDAQ:QNTM opened at $2.83 on Thursday. Quantum Biopharma has a one year low of $2.07 and a one year high of $31.91. The firm has a 50-day simple moving average of $4.23 and a 200-day simple moving average of $4.34. The firm has a market cap of $18.11 million, a P/E ratio of -0.34 and a beta of 0.43.

Analysts Set New Price Targets

Several brokerages have weighed in on QNTM. Wall Street Zen downgraded shares of Quantum Biopharma from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 18th. Weiss Ratings lowered Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Quantum Biopharma has an average rating of “Sell”.

Hedge Funds Weigh In On Quantum Biopharma

An institutional investor recently bought a new position in Quantum Biopharma stock. Jane Street Group LLC purchased a new position in Quantum Biopharma Ltd. (NASDAQ:QNTM) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,892 shares of the company’s stock, valued at approximately $80,000. Jane Street Group LLC owned 0.29% of Quantum Biopharma at the end of the most recent quarter. Institutional investors own 1.24% of the company’s stock.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.